All articles by Patrick Kingsland

Inside CARB-X: can this new model for research fix a broken antibiotics market?

Resistance to antibiotics is rising but the business model for developing new antibiotic drugs is broken. Could CARB-X, the world’s largest public-private partnership devoted to antibacterial research and development, be the answer? Patrick Kingsland finds out more from CARB-X executive director Kevin Outterson.